Background: Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a major clinical challenge. Although ponatinib, a third-generation TKI, improves outcomes for patients with BCR-ABLdependent mechanisms of resistance, including the T315I mutation, a proportion of patients may have or develop BCR-ABL-independent resistance and fail ponatinib treatment. By modeling ponatinib resistance and testing samples from these CML patients, it is hoped that an alternative drug target can be identified and inhibited with a novel compound. Methods: Two CML cell lines with acquired BCR-ABL-independent resistance were generated following culture in ponatinib. RNA sequencing and gene ontology (GO) enrichment were used to detect aberrant transcriptional response in ponatinibresistant cells. A validated oncogene drug library was used to identify US Food and Drug Administration-approved drugs with activity against TKI-resistant cells. Validation was performed using bone marrow (BM)-derived cells from TKI-resistant patients (n ¼ 4) and a human xenograft mouse model (n ¼ 4-6 mice per group). All statistical tests were two-sided. Results: We show that ponatinib-resistant CML cells can acquire BCR-ABL-independent resistance mediated through alternative activation of mTOR. Following transcriptomic analysis and drug screening, we highlight mTOR inhibition as an alternative therapeutic approach in TKI-resistant CML cells. Additionally, we show that catalytic mTOR inhibitors induce autophagy and demonstrate that genetic or pharmacological inhibition of autophagy sensitizes ponatinib-resistant CML cells to death induced by mTOR inhibition in vitro (% number of colonies of control [SD], NVP-BEZ235 vs NVP-BEZ235þHCQ: 45.0[17.9]% vs 24.0[8.4]%, P ¼ .002) and in vivo (median survival of NVP-BEZ235-vs NVP-BEZ235þHCQ-treated mice: 38.5 days vs 47.0 days, P ¼ .04). Conclusion: Combined mTOR and autophagy inhibition may provide an attractive approach to target BCR-ABL-independent mechanism of resistance.
Chronic myeloid leukemia (CML) is caused by a reciprocal translocation giving rise to the Philadelphia (Ph) chromosome within a hemopoietic stem cell (1) . This leads to transcription/translation of BCR-ABL, a constitutively active tyrosine kinase (2) . CML usually presents in a chronic phase (CP), before progressing to accelerated phase (AP) and terminal blast crisis (BC) if left untreated. Imatinib has statistically significantly improved life expectancy by inducing cytogenetic and molecular responses in the majority of patients in CP (3) . However, the pathway to "cure" has been tempered by drug intolerance, insensitivity of CML stem cells to TKIs (4) (5) (6) (7) , and drug resistance (8, 9) .
The mechanisms of drug resistance have been extensively investigated and can be classified as BCR-ABL dependent or independent. It is known that approximately 50% of patients who relapse on imatinib have mutations within the ABL kinase domain, affecting imatinib binding within the kinase pocket (10) . Dasatinib, nilotinib, and/or bosutinib have activity against the majority of imatinib-resistant mutants, except T315I (11) . Although the development of a TKI active against the T315I mutant has proven challenging, ponatinib (AP24534), a third-generation TKI, has activity against T315I in vitro (12) and in patients (13, 14) . Ponatinib was tested in the PACE clinical trial in patients with the T315I mutation or who are resistant/intolerant to either dasatinib or nilotinib. Findings from PACE show that major molecular response (MMR) is achieved in 56% of CP patients with the T315I mutation (14) , although a proportion of patients will ultimately develop or be proven to have ponatinib-resistant disease.
Patients whose disease fails multiple TKI treatments without having ABL kinase domain mutations predominantly represent a population with BCR-ABL-independent mechanisms of resistance. For this group of patients, the treatment options are very limited, and only 27% of "resistant/intolerant" patients achieved MMR in the PACE trial (14) . Although much less is known about BCR-ABL-independent resistance, a recent genetic study has shown that it can vary between individuals, often suggesting re-activation of signaling pathways involved in CML pathogenesis (15) . Additionally, studies have shown that increased FGF2 in the BM (16) or activation of LYN (17, 18) may be responsible for the survival of cells following BCR-ABL inhibition. However, ponatinib, which has activity against FGF receptor and LYN kinase (12) , has been shown to overcome FGF2-mediated resistance in CML patients without kinase domain mutations (16) and to be effective against many imatinibresistant CML cell lines (19) , highlighting the importance of using ponatinib as the TKI of choice for investigation of acquired BCR-ABL-independent resistance in CML.
The goals of the current study were to examine what drives BCR-ABL-independent resistance and identify clinically relevant oncology compounds with activity against ponatinib-resistant cells.
Methods

Transplantation Experiments
Human KCL22
Pon-Res cells, labeled with lentiviral firefly luciferase, were transplanted via tail vein injection into eight-to 12-week-old female NSG mice (four to six mice were assigned per drug arm per experiment). For in vivo treatment, after one week, the mice were treated with vehicle control, HCQ, NVP-BEZ235, or the combination of NVP-BEZ235/HCQ for four to five weeks. 
Gene Ontology Term Enrichment Analysis
Gene ontology (GO) term enrichment analysis was carried out using the GO.db (v3.2.2) and GOstats (v2.36.0) Bioconductor libraries in R; P values were generated using a hypergeometric test and adjusted for multiple testing (20) .
Statistical Analysis
Error bars represent SD. Statistical analyses were performed using the two-tailed Student's t test or Gehan-Breslow Wilcoxon test. A P value of .05 or less was taken to be statistically significant. Detailed information on all other methods can be found in the Supplementary Material (available online).
Results
Cellular Modeling of BCR-ABL-Independent Mechanisms of Resistance
Imatinib-resistant cell lines are often sensitive to more potent second-generation TKIs and/or ponatinib and are therefore not an ideal model to investigate acquired resistance to all available TKIs (Supplementary Figure 1 , A-C, available online). Hence, we aimed to develop a ponatinibresistant cell line with acquired BCR-ABL-independent resistance. KCL22 cells (human myeloid BC CML cell line) were grown in increasing concentrations of ponatinib for a prolonged period. Ponatinib-resistant (KCL22 Pon-Res ) clones continued to proliferate when exposed to 100 nM ponatinib ( Figure 1A) . Sequencing of the BCR-ABL kinase domain showed no kinase domain mutations (data not shown). Measuring tyrosine 207 phosphorylation of CRKL, a direct BCR-ABL substrate, revealed that BCR-ABL activity was inhibited to similar levels as in KCL22 
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when combined with complete BCR-ABL inhibition ( Figure 3B ). Subsequent target association analysis enriched for and highlighted microtubule, proteasome, and allosteric mTORC1 inhibitors (Supplementary Figure 3B , available online). However, these microtubule and proteasome inhibitors have known toxicities in the clinic. With IC50 levels for everolimus, sirolimus, and temsirolimus all below 200 nM (indicating on-target effect), regardless of whether used alone or in combination with ponatinib (Supplementary Figure 3 , A-C, available online), we decided to focus our subsequent work on mTOR as a potential target for TKI resistance. This decision was also supported by the data shown in Figure 2B and Supplementary Figure 2 (available online), which suggest that sustained mTORC1 activity may support survival of KCL22 Pon-Res cells following TKI treatment.
Sensitivity of KCL22
Pon-Res and TKI-Resistant Primary
CML Cells to Catalytic mTOR Inhibitors
To date, sirolimus (rapamycin) and rapamycin analogues (allosteric mTORC1 inhibitors) (Supplementary Table 2 , available online) have only shown modest efficacy in clinical trials (23).
This is believed to be because they are incomplete, substrateselective mTORC1 inhibitors (24) . However, with the development of catalytic mTOR inhibitors, it is still hoped that mTOR represents a druggable target in malignancies driven by activation of the mTOR pathway. To confirm deeper mTORC1 inhibition with catalytic mTOR inhibitors, KCL22 Pon-Res cells were treated with PI-103 and its derivative NVP-BEZ235 (which inhibit both mTORC1 and mTORC2 and have activity against all PI3K isoforms [25, 26] ) and compared with rapamycin ( Figure 4A ). In line with previous studies, rapamycin had little effect on phosphorylation of 4E-BP1, whereas PI-103 and NVP-BEZ235 (using IC50 concentrations) led to reduction in 4E-BP1 phosphorylation, demonstrating more potent mTORC1 inhibition ( Figure 4B ). Seventy-two hours of drug treatment led to modest induction of apoptosis by rapamycin, with more extensive and statistically significant apoptosis observed following NVP-BEZ235 treatment (44.2[9.6]%, P ¼ .02), whereas TKIs had no effect ( Figure 4C ). Similar effects were seen in colony forming cell (CFC) assay (data not shown). To test if these findings would replicate using different BCR-ABL-positive cell lines, we generated ponatinib-resistant BaF3 cells (BaF3 Encouraged by these results and to translate our findings closer to the clinic, we compared the effect of ponatinib with various catalytic mTOR inhibitors on available progenitor cells derived from the BM of a patient who had failed to achieve complete cytogenetic response following first-, second-, and thirdgeneration TKI treatments. Importantly, while ponatinib was ineffective, the catalytic mTOR inhibitors NVP-BEZ235 (26), Gedatolisib (27, 28) , Apitolisib (29, 30) , VS-5584 (31), and AZD8055 (32) all induced apoptosis over and above the ponatinib-treated arm (Supplementary Figure 5 , available online).
To further understand the mechanism by which NVP-BEZ235 induced death, we performed RNA-seq on parental KCL22 and KCL22 Pon-Res . Strikingly, while ponatinib had no effect on gene transcription in KCL22
Pon 
The Effect of Catalytic mTORC1 Inhibition on Autophagy in KCL22
Pon-Res Cells mTORC1 not only regulates mRNA translation, but is also the master regulator of autophagy (macro-autophagy) (33, 34) . To assess autophagy flow, we generated KCL22 Pon-Res cell lines stably expressing fluorescence-tagged human LC3B (mRFP-GFP-LC3B) that enable different stages of autophagy to be visualized by fluorescence microscopy (35) . The appearance of red/green puncta (yellow when overlapped) indicates autophagosomes, and as GFP is highly susceptible to the low pH within the lysosomes, a "red only" signal indicates autolysosomes. This process can be inhibited by hydroxychloroquine (HCQ), which inhibits autophagy at a late stage by preventing the fusion of autophagosomes and lysosomes, leading to build-up of yellow fluorescence. NVP-BEZ235 treatment increased puncta exhibiting a "red only" signal (autophagy flow complete) in KCL22 , an E1-like enzyme and essential autophagy gene required for LC3 lipidation, was targeted using CRISPR-Cas9. ATG7 knockdown inhibited LC3B-II formation and autophagy, measured by a decrease in LC3B-II levels and an increase in the autophagy substrate SQSTM1/p62 (36,37) ( Figure 5C ), and indeed sensitized cells to death following NVP-BEZ235-mediated mTOR inhibition (P ¼ .06) ( Figure 5D ). Similarly, RNAi-mediated ATG7 knockdown statistically significantly increased the effect of the NVP-BEZ235 on apoptosis, confirming that autophagy plays a protective role in KCL22 Pon-Res cells following inhibition of mTORC1 (P ¼ .002) ( Figure 5E ).
The Effect of Pharmacological Inhibition of Autophagy and NVP-BEZ235 Treatment In Vivo and in TKIResistant Primary CML Cells
We next tested whether mTOR inhibition can interfere with leukemia initiation when combined with pharmacological autophagy inhibition. KCL22 Pon-Res cells were labeled with lentiviral luciferase and treated ex vivo with NVP-BEZ235, HCQ, and the combination. Following drug treatment, cells were injected into NSG mice, which were then monitored weekly by luciferase bioimaging. At week 4, there was a marked delay in leukemia development in mice engrafted with cells treated with the combination ( Figure 6A ). The combination treatment also statistically significantly prolonged overall survival of xenografted NSG mice when compared with NVP-BEZ235 single treatment (P ¼ .01) ( Figure 6A ). To test the tolerability and efficacy of this drug combination, we injected luciferase-expressing KCL22
Pon-Res cells into NSG mice. Following evidence of engraftment, the xenografted mice were treated for up to five weeks. By week 3, bio-imaging showed leukemia development in untreated and HCQ-treated mice ( Figure 6B ). By five weeks, all untreated and HCQ-treated mice had to be killed, together with two out of five mice treated with NVP-BEZ235 alone. Mice showed few signs of toxicity, and the combination statistically significantly extended the survival of mice when compared with NVP-BEZ235 single treatment (median survival NVP-BEZ235 vs NVP-BEZ235þHCQ: 38.5 days vs 47.0 days, P ¼ .04) ( Figure 6B ). Finally, we compared the effect of NVP-BEZ235 in combination with HCQ with ponatinib on cells derived from the BM of four patients who had failed to achieve cytogenetic response following first-, second-, or third-generation TKI treatments (Supplementary Table 3 , available online). Importantly, NVP-BEZ235 had a greater effect on survival of progenitor cells in these patients ( Figure 6C To test the effect of this combination on normal cells, non-CML cells (derived from patients with Phnegative, nonmyeloid hematological malignancies) were treated with ponatinib, NVP-BEZ235 alone, and in combination with HCQ, and compared with a cytotoxicity of 10 nM omacetaxine treatment. This revealed that while omacetaxine substantially affected the CFC potential of normal progenitor cells, the combination of NVP-BEZ235 and HCQ had only a minimal effect ( Figure 6D ).
Discussion
Despite the promising results in the PACE trial, where ponatinib induced rapid and durable responses in CP-CML patients, it is associated with considerable cardiovascular toxicity that may be dose-dependent. Additionally, a proportion of patients taking ponatinib already have or will develop BCR-ABL-independent mechanisms of resistance, and therefore fail ponatinib treatment. Therefore, it is hoped that this patient population that currently experiences rare response to TKI treatment and very short survival may share an alternative drug target that can be inhibited with a novel compound. We, therefore, for the first time, generated a ponatinib-resistant cell line, which developed BCR-ABL-independent activation of mTOR. This afforded us a unique opportunity to search for drugs that are effective against ponatinib-resistant CML cells. Our screen and subsequent testing of catalytic mTOR inhibitors revealed that NVP-BEZ235 had increased potency in inhibiting mTORC1 in ponatinib-resistant cells. This correlated with potent transcriptional response and induction of apoptosis, in agreement with previous studies where catalytic mTOR inhibitors, such as OSI-027 and PP242 (or dual PI3K/mTOR inhibitors, such as PI-103 and NVP-BEZ235), have been shown to prevent expansion of Ph-positive acute lymphoblastic leukemia cells in vivo (38) , to sensitize CML cells to nilotinib (39, 40) , and to be effective in targeting CML cells in vitro (41, 42) . Critically, we also showed that NVP-BEZ235 was more effective than ponatinib against available primary cells obtained from heavily pretreated TKI-resistant CML patients. Although further investigation will be required to confirm the exact mechanism of resistance in each patient (requires optimized protocols for rare BM-aspirated cells), this provides a rationale for testing catalytic mTOR inhibitors in the clinic for patients who do not respond to BCR-ABL inhibitors.
A phase I dose-finding study of NVP-BEZ235 is ongoing in patients with relapsed or refractory acute leukemia (NCT01756118). Based on a phase I trial in patients with advanced solid tumors, the recommended dose for NVP-BEZ235 is 300 mg twice daily (BID), which is still expected to inhibit mTORC1/2 according to pharmacodynamic data (43) . However, recent results from a phase II trial for patients with everolimus- Relative colony number show that many patients experience toxicities on 300 mg BID, although this may also reflect the fragility of the heavily pretreated patients with this aggressive cancer (44) . It is clear that the depth of response to TKI is the major driver for sustained remissions, hence the need to rapidly reduce overall leukemic cell burden and ideally to reduce the numbers of BM-located cells (45) . We showed that HCQ treatment (a nonspecific autophagy inhibitor that is being tested in more than 30 active clinical trials [46] ) inhibited autophagy flow and enhanced death following NVP-BEZ235, both in vitro and in a xenograft model of CML. Importantly, we also showed that genetic autophagy inhibition sensitized CML cells to death, indicating that the main additive effect of HCQ was due to a block in the autophagy process, but not off target effect.
A recent phase I trial in patients with advanced solid tumors and melanoma shows that HCQ is safe and tolerable and has some antitumor activity when used in combination with temsirolimus-mediated mTOR inhibition (47) . Although our results on normal blood cells suggest that HCQ and NVP-BEZ235-mediated mTOR inhibition may be tolerated with regards to myelosuppression, results from phase I trials are awaited for different innovative catalytic mTOR inhibitors such as Gedatolisib, Apitolisib, VS5584, and AZD8055 (all in phase I; Apitolisib in phase II). The outcome of these studies may determine the most suitable catalytic mTOR inhibitor (in terms of efficacy and tolerability) to be taken forward for combination studies.
Given that the mechanism(s) of resistance to TKIs may vary from patient to patient, potential limitations of this study should be considered. First, the in vitro studies of primary CML cells in response to the catalytic mTOR inhibitor(s) presented here were confined to a relatively small number of TKI-resistant CML patients' samples. Additionally, HCQ is nonspecific autophagy inhibitor, and development of more specific and/or more potent autophagy inhibitors might be required to inhibit autophagy in BM-located cells in CML patients.
We conclude that catalytic mTOR inhibitors may be effective for patients with BCR-ABL-independent resistance and that pharmacological autophagy inhibition will further enhance their efficacy. This is particularly important for this heavily pretreated population because treatment options for patients who fail all currently available TKIs, including ponatinib, are very limited.
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